Elevar Therapeutics Announces the Formation and Members of Scientific Advisory Board
Elevar plans for major 2025 oncology regulatory milestones- March 2025 PDUFA date and launch preparation for unresectable hepatocellular carcinoma- NDA Submission for lirafugratinib in second half 2025 for FGFR2 driven cholangiocarcinoma
FORT LEE, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a portfolio company of HLB Co., Ltd., today announced the formation of its Scientific Advisory Board (SAB) with internationally renowned experts in the discovery and development of next generation hepatocellular carcinoma and cholangiocarcinoma cancer therapies.
'We proudly welcome our newly formed Scientific Advisory Board, a distinguished group of oncology clinicians who will play a crucial role in supporting our research and development strategy. Their individual and collective expertise will be invaluable as we strive to make a meaningful impact in the fight against cancer,' commented Chris Galloway, M.D., senior vice president of clinical development and medical affairs at Elevar.
Mitesh Borad, M.D.
Mitesh J. Borad, M.D., is the Getz Family Research Professor and leads the Novel Therapeutics and Modalities Program at Mayo Clinic. Dr. Borad is an internationally recognized expert for treating patients with cholangiocarcinoma and has been extensively involved in developing novel cancer therapeutic platforms that leverage genomic medicine and gene/virus therapies, with a focus on tumors of the liver, bile ducts and pancreas. He has led the clinical development of novel anti-cancer agents in more than 50 first-in-human studies, including a multi-institutional team with collaborators at Mayo Clinic and the Translational Genomics Research Institute, which led to the discovery of fibroblast growth factor 2 (FGFR2) fusions in patients with intrahepatic cholangiocarcinoma, with the first demonstration of anti-tumor activity with FGFR inhibitors in this patient population. Subsequent work led to the FDA approval of three FGFR inhibitor cancer therapies.
Richard Kim, M.D.
Dr. Richard Kim is a Service Chief of Medical Gastrointestinal Oncology and Senior Member in the Gastrointestinal Oncology Department at Moffitt Cancer Center and a Professor of Oncology at the University of South Florida College of Medicine. Before joining Moffitt in 2010, Dr. Kim was an associate physician in gastrointestinal malignancies at the Cleveland Clinic Taussig Cancer Center and a clinical assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, OH. Dr. Kim's clinical and research interests focus on gastrointestinal tumors, in particular hepatobiliary and colon cancer. He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I, II and III trials using immunotherapy and novel targeted agents.
Daneng Li, M.D.
Daneng Li, M.D. is an Associate Professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li's clinical and academic research is focused on the multidisciplinary approach to treatment of patients with neuroendocrine tumors (NETs). He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics.
Rachna T Shroff, M.D., M.S.
Rachna T. Shroff, MD, MS, FASCO, serves as associate director of Clinical Investigations and co-leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center (UACC) and is a professor in the Department of Medicine, chief of the Division of Hematology and Oncology, medical director for the Oncology Service Line and associate dean for Clinical and Translational Research for the University of Arizona College of Medicine – Tucson. Dr. Shroff joined UACC from MD Anderson Cancer Center in Houston. She is a clinical and translational investigator focused on developing novel therapies for pancreatic and hepatobiliary cancers and has led numerous clinical trials focusing on pancreaticobiliary tumors. She was the national principal investigator for SWOG 1815, which investigated a triplet chemotherapy regimen as a potential new standard of care for biliary cancers.
About Elevar Therapeutics
Elevar Therapeutics, Inc., a fully owned subsidiary of HLB Group, is a fully integrated biopharmaceutical company built on the promise of elevating treatment outcomes for patients who have limited or inadequate therapeutic options. With expertise rooted in oncology, Elevar is focused on identifying and developing promising medicines for complex yet under-treated health conditions. Elevar's lead proprietary drug candidate is rivoceranib. The NDA for rivoceranib in combination with camrelizumab as a therapy for advanced or metastatic hepatocellular carcinoma (HCC) is currently under review by the FDA with a PDUFA action date scheduled for March 20, 2025. On December 2, 2023, Elevar acquired worldwide rights to develop and commercialize lirafugratinib (RLY-4008), an FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma (CCA) and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors. An NDA submission for lirafugratinib is planned for 2025.
Additional information is available at www.Elevar Therapeutics.com.
About HLB Group
The HLB Group is comprised of HLB Inc. (KOSDAQ:028300) and its affiliates with a diverse portfolio across biopharma, lifestyle, marine business, semiconductor and energy, united by the mission of improving all aspects of human life. Members of the HLB Group include HLB Innovation (KOSDAQ: 024850), HLB BioStep (KOSDAQ:278650), HLB Pharmaceutical (KOSDAQ:047920), HLB Life Science (KOSDAQ:067630), HLB Therapeutics (KOSDAQ:115450), HLB Panagene (KOSDAQ:046210) and HLB Global (KOSDAQ:003580). HLB Group's overseas affiliates include Elevar Therapeutics, Immunomic Therapeutics, a nucleic acid immunotherapy platform company, and Verismo Therapeutics, a CAR T platform oncology company, and a fully owned subsidiary of HLB Innovation, both based in the United States.
Contacts
Media: Jeanette BressiHead, Corporate Communications jbressi@elevartherapeutics.com 609-439-3997
Investors: Wade SmithChief Financial & Business Officer wsmith@elevartherapeutics.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
8 hours ago
- Time Business News
Fiebrigen: Meaning, Symptoms, and How to Cope
The word fiebrigen comes from German and refers to a feverish state — both physically and emotionally. It's that heavy feeling when your skin is warm, your body aches, and your mind feels trapped in a fog. The watercolor painting above captures this perfectly: a person looking down, weary, surrounded by cloud-like shades that symbolize confusion and illness. But being fiebrigen doesn't always mean you have a high fever. Sometimes it's the body's way of showing stress, exhaustion, or the early stages of sickness. Let's explore what fiebrigen really means, what causes it, and how to take care of yourself when you feel this way. In simple terms, fiebrigen describes: Feeling feverish or unwell Warmth in the body, sometimes without measurable fever Weakness, fatigue, or body aches Mental fog or restlessness It's not just a medical condition — it can also describe an emotional state of being weighed down, restless, or lost in thought. There are many reasons why someone may feel fiebrigen. Some are physical, others emotional: Infections – Cold, flu, or bronchitis often begin with feverish feelings. Stress and Anxiety – Mental strain can cause physical symptoms like fatigue and warmth. Inflammation – The immune system raises body temperature to fight infection. Exhaustion – Lack of sleep or overwork leaves the body feeling heavy and feverish. Dehydration – Without enough fluids, the body overheats and feels weak. Symptom What It Might Indicate Warm or flushed skin Early sign of fever or body overheating Aching muscles/joints Common with flu, cold, or physical overwork Headache and tired eyes Stress, dehydration, or infection Mental fog, confusion Lack of sleep, exhaustion, or high fever Chills or sweating Body regulating temperature during illness The image reflects not only physical fever but also the emotional burden of being fiebrigen. Many people feel sadness, irritability, or even a sense of being lost when unwell. Just as the watercolor blurs colors into clouds, feverishness can blur the line between body and mind. If you feel fiebrigen, here are simple but effective steps: Rest Deeply – Sleep is the body's best healer. – Sleep is the body's best healer. Hydrate – Drink water, herbal teas, or broth. Dehydration worsens fever. – Drink water, herbal teas, or broth. Dehydration worsens fever. Cool Compresses – A damp cloth on the forehead can soothe discomfort. – A damp cloth on the forehead can soothe discomfort. Eat Light – Soups, fruits, and vegetables are easier to digest. – Soups, fruits, and vegetables are easier to digest. Check Temperature – Monitor fever regularly. If it rises above 39°C (102°F), seek medical advice. Not every fiebrigen moment requires medical help, but you should see a doctor if: Fever is very high or lasts more than 3 days You feel extreme weakness or dehydration You experience chest pain, breathing problems, or confusion A child or elderly person has fiebrigen symptoms (higher risk) Trusted health sources like Mayo Clinic and WebMD recommend not ignoring persistent feverish states. Being fiebrigen is more than just having a fever. It's a condition that blends body, mind, and emotions. The image of the weary young man surrounded by cloudy colors mirrors the experience: heavy, restless, but also a reminder to slow down and care for yourself. Whether caused by flu, stress, or exhaustion, listening to your body is key. Rest, hydration, and mindful care can help you recover faster and prevent further illness. Q1. Does fiebrigen always mean fever? No, sometimes you feel fiebrigen without an actual rise in temperature. Q2. Can emotions make me feel fiebrigen? Yes. Stress, sadness, or burnout can cause fever-like symptoms. Q3. What's the best home remedy? Plenty of rest, fluids, and a light diet usually help. Q4. Is fiebrigen dangerous? Mild feverish states aren't usually dangerous, but persistent high fever should not be ignored. Q5. How do children show fiebrigen symptoms? TIME BUSINESS NEWS
Associated Press
12 hours ago
- Associated Press
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Lockheed Martin Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lockheed Martin Corporation (NYSE: LMT) between January 23, 2024 and July 21, 2025, both dates inclusive (the 'Class Period'), of the important September 26, 2025 lead plaintiff deadline. SO WHAT: If you purchased Lockheed Martin securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Lockheed Martin class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 26, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Lockheed Martin lacked effective internal controls regarding its purportedly risk adjusted contracts including the reporting of its risk adjusted profit booking rate; (2) Lockheed Martin lacked effective procedures to perform reasonably accurate comprehensive reviews of program requirements, technical complexities, schedule, and risks; (3) Lockheed Martin overstated its ability to deliver on its contract commitments in terms of cost, quality and schedule; (4) as a result, Lockheed Martin was reasonably likely to report significant losses; and (5) as a result of the foregoing, defendants' positive statements about Lockheed Martin's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Lockheed Martin class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Associated Press
12 hours ago
- Associated Press
SRPT IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action
NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the 'Class Period'), of the important August 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sarepta securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Sarepta class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (3) the severity of adverse events from ELEVIDYS treatment would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (4) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Sarepta class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
